Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

Jillian G. Baker, Sheila M. Gardiner, Jeanette Woolard, Christophe Fromont, Gopal Jadhav, Shailesh N. Mistry, Kevin S.J. Thompson, Barrie Kellam, Stephen J. Hill, Peter M. Fischer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

β-Blockers reducemortality andimprove symptoms inpeople withheartdisease;however, current clinically available β-blockers have poor selectivity for the cardiac β1-adrenoceptor (AR) over the lung β2-AR. Unwanted β2-blockade risks causing life-threatening bronchospasm and reduced efficacy of β2-agonist emergency rescue therapy. Thus, current life-prolonging β-blockers are contraindicated in patients with both heart disease and asthma. Here, we describeNDD-713 and -825, novel highly β1-selective neutral antagonists with good pharmaceutical properties that can potentially overcome this limitation. Radioligand binding studies and functional assays that use human receptors expressed inChinesehamster ovary cellsdemonstrate that NDD-713 and-825 have nanomolar β1-AR affinity >500-fold β1-AR vs. β2-AR selectivity and no agonism. Studies in conscious rats demonstrate that these antagonists are orally bioavailable and cause pronounced β1-mediated reduction of heart rate while showing no effect on β2-mediated hindquarters vasodilatation. These compounds also have good disposition properties and show no adverse toxicologic effects. They potentially offer a truly cardioselective β-blocker therapy for the large number of patientswith heart and respiratory or peripheral vascular comorbidities.

Original languageEnglish (US)
Pages (from-to)3150-3166
Number of pages17
JournalFASEB Journal
Volume31
Issue number7
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Pulmonary diseases
Adrenergic Receptors
Cardiovascular Diseases
Bronchial Spasm
Emergency Treatment
Vasodilation
Blood Vessels
Comorbidity
Rats
Ovary
Heart Diseases
Assays
Asthma
Heart Rate
Lung
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Baker, J. G., Gardiner, S. M., Woolard, J., Fromont, C., Jadhav, G., Mistry, S. N., ... Fischer, P. M. (2017). Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB Journal, 31(7), 3150-3166. https://doi.org/10.1096/fj.201601305R

Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. / Baker, Jillian G.; Gardiner, Sheila M.; Woolard, Jeanette; Fromont, Christophe; Jadhav, Gopal; Mistry, Shailesh N.; Thompson, Kevin S.J.; Kellam, Barrie; Hill, Stephen J.; Fischer, Peter M.

In: FASEB Journal, Vol. 31, No. 7, 01.07.2017, p. 3150-3166.

Research output: Contribution to journalArticle

Baker, JG, Gardiner, SM, Woolard, J, Fromont, C, Jadhav, G, Mistry, SN, Thompson, KSJ, Kellam, B, Hill, SJ & Fischer, PM 2017, 'Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease', FASEB Journal, vol. 31, no. 7, pp. 3150-3166. https://doi.org/10.1096/fj.201601305R
Baker, Jillian G. ; Gardiner, Sheila M. ; Woolard, Jeanette ; Fromont, Christophe ; Jadhav, Gopal ; Mistry, Shailesh N. ; Thompson, Kevin S.J. ; Kellam, Barrie ; Hill, Stephen J. ; Fischer, Peter M. / Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. In: FASEB Journal. 2017 ; Vol. 31, No. 7. pp. 3150-3166.
@article{48268c28ecba4334a139039dbe1baabd,
title = "Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease",
abstract = "β-Blockers reducemortality andimprove symptoms inpeople withheartdisease;however, current clinically available β-blockers have poor selectivity for the cardiac β1-adrenoceptor (AR) over the lung β2-AR. Unwanted β2-blockade risks causing life-threatening bronchospasm and reduced efficacy of β2-agonist emergency rescue therapy. Thus, current life-prolonging β-blockers are contraindicated in patients with both heart disease and asthma. Here, we describeNDD-713 and -825, novel highly β1-selective neutral antagonists with good pharmaceutical properties that can potentially overcome this limitation. Radioligand binding studies and functional assays that use human receptors expressed inChinesehamster ovary cellsdemonstrate that NDD-713 and-825 have nanomolar β1-AR affinity >500-fold β1-AR vs. β2-AR selectivity and no agonism. Studies in conscious rats demonstrate that these antagonists are orally bioavailable and cause pronounced β1-mediated reduction of heart rate while showing no effect on β2-mediated hindquarters vasodilatation. These compounds also have good disposition properties and show no adverse toxicologic effects. They potentially offer a truly cardioselective β-blocker therapy for the large number of patientswith heart and respiratory or peripheral vascular comorbidities.",
author = "Baker, {Jillian G.} and Gardiner, {Sheila M.} and Jeanette Woolard and Christophe Fromont and Gopal Jadhav and Mistry, {Shailesh N.} and Thompson, {Kevin S.J.} and Barrie Kellam and Hill, {Stephen J.} and Fischer, {Peter M.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1096/fj.201601305R",
language = "English (US)",
volume = "31",
pages = "3150--3166",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "7",

}

TY - JOUR

T1 - Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

AU - Baker, Jillian G.

AU - Gardiner, Sheila M.

AU - Woolard, Jeanette

AU - Fromont, Christophe

AU - Jadhav, Gopal

AU - Mistry, Shailesh N.

AU - Thompson, Kevin S.J.

AU - Kellam, Barrie

AU - Hill, Stephen J.

AU - Fischer, Peter M.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - β-Blockers reducemortality andimprove symptoms inpeople withheartdisease;however, current clinically available β-blockers have poor selectivity for the cardiac β1-adrenoceptor (AR) over the lung β2-AR. Unwanted β2-blockade risks causing life-threatening bronchospasm and reduced efficacy of β2-agonist emergency rescue therapy. Thus, current life-prolonging β-blockers are contraindicated in patients with both heart disease and asthma. Here, we describeNDD-713 and -825, novel highly β1-selective neutral antagonists with good pharmaceutical properties that can potentially overcome this limitation. Radioligand binding studies and functional assays that use human receptors expressed inChinesehamster ovary cellsdemonstrate that NDD-713 and-825 have nanomolar β1-AR affinity >500-fold β1-AR vs. β2-AR selectivity and no agonism. Studies in conscious rats demonstrate that these antagonists are orally bioavailable and cause pronounced β1-mediated reduction of heart rate while showing no effect on β2-mediated hindquarters vasodilatation. These compounds also have good disposition properties and show no adverse toxicologic effects. They potentially offer a truly cardioselective β-blocker therapy for the large number of patientswith heart and respiratory or peripheral vascular comorbidities.

AB - β-Blockers reducemortality andimprove symptoms inpeople withheartdisease;however, current clinically available β-blockers have poor selectivity for the cardiac β1-adrenoceptor (AR) over the lung β2-AR. Unwanted β2-blockade risks causing life-threatening bronchospasm and reduced efficacy of β2-agonist emergency rescue therapy. Thus, current life-prolonging β-blockers are contraindicated in patients with both heart disease and asthma. Here, we describeNDD-713 and -825, novel highly β1-selective neutral antagonists with good pharmaceutical properties that can potentially overcome this limitation. Radioligand binding studies and functional assays that use human receptors expressed inChinesehamster ovary cellsdemonstrate that NDD-713 and-825 have nanomolar β1-AR affinity >500-fold β1-AR vs. β2-AR selectivity and no agonism. Studies in conscious rats demonstrate that these antagonists are orally bioavailable and cause pronounced β1-mediated reduction of heart rate while showing no effect on β2-mediated hindquarters vasodilatation. These compounds also have good disposition properties and show no adverse toxicologic effects. They potentially offer a truly cardioselective β-blocker therapy for the large number of patientswith heart and respiratory or peripheral vascular comorbidities.

UR - http://www.scopus.com/inward/record.url?scp=85021685950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021685950&partnerID=8YFLogxK

U2 - 10.1096/fj.201601305R

DO - 10.1096/fj.201601305R

M3 - Article

VL - 31

SP - 3150

EP - 3166

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 7

ER -